Electromed price target raised to $35 from $29 at Roth Capital

Roth Capital analyst Kyle Bauser raised the firm’s price target on Electromed (ELMD) to $35 from $29 and keeps a Buy rating on the shares. The company reported better-than-expected results and outlined the expectation in FY26 to deliver double-digit top-line growth with expanded operating leverage, the analyst tells investors in a research note. Electromed shares remain highly undervalued given the company’s market-leading position within the underserved bronchiectasis space, strong earning’s profile, clean balance sheet, and improving operating efficiencies, Roth added.